HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(S)- 6- ((1- (4- chlorophenyl)ethyl)amino)- 1- cyclopentyl- 1,5,6,7- tetrahydro- 4H- pyrazolo(3,4- day)pyrimidin- 4- one

a phosphodiesterase-9A (PDE9A) inhibitor that protects against cardiac hypertrophy in rats

Also Known As:

(S)-C33; C33(S)

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - (S)-6-((1-(4-chlorophenyl)ethyl)amino)-1-cyclopentyl-1,5,6,7-tetrahydro-4H-pyrazolo(3,4-day)pyrimidin-4-one: 1
  - Pyrimidines: 510
    - (S)-6-((1-(4-chlorophenyl)ethyl)amino)-1-cyclopentyl-1,5,6,7-tetrahydro-4H-pyrazolo(3,4-day)pyrimidin-4-one: 1

Experts

1.	Cai, Si-Dong: 1 article (09/2017)
2.	Chen, Shao-Rui: 1 article (09/2017)
3.	Feng, Guo-Shuai: 1 article (09/2017)
4.	He, Ping: 1 article (09/2017)
5.	Huang, Yi: 1 article (09/2017)
6.	Li, Jing-Yan: 1 article (09/2017)
7.	Li, Zhuo-Ming: 1 article (09/2017)
8.	Liu, Pei-Qing: 1 article (09/2017)
9.	Luo, Hai-Bin: 1 article (09/2017)
10.	Wang, Pan-Xia: 1 article (09/2017)

Related Diseases

1.	Cardiomegaly (Heart Hypertrophy) 09/01/2017 - "The present study sought to investigate the effects and underlying mechanisms of C33(S), a novel selective PDE9A inhibitor, on cardiac hypertrophy in vitro and in vivo. " 09/01/2017 - "C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling." 09/01/2017 - "Our results demonstrate that C33(S) effectively protects against cardiac hypertrophy and postpones the transition to heart failure, suggesting that it is a promising agent in the treatment of cardiac diseases."
2.	Heart Failure 09/01/2017 - "In ISO-treated rats, oral administration of C33(S) (9, 3, and 1 mg·kg-1·d-1, for 3 consecutive weeks) significantly increased fractional shortening (43.55%±3.98%, 54.79%±1.95%, 43.98%±7.96% vs 32.18%±6.28%), ejection fraction (72.97%±4.64%, 84.29%±1.56%, 73.41%±9.37% vs 49.17%±4.20%) and cardiac output (60.01±9.11, 69.40±11.63, 58.08±8.47 mL/min vs 48.97±2.11 mL/min) but decreased the left ventricular internal diameter, suggesting that the transition to heart failure was postponed by C33(S). " 09/01/2017 - "We further revealed that C33(S) significantly elevated intracellular cGMP levels, phosphorylation of phospholamban (PLB) and expression of SERCA2a in PE-treated NRCMs in vitro and in ISO-induced heart failure model in vivo. " 09/01/2017 - "Our results demonstrate that C33(S) effectively protects against cardiac hypertrophy and postpones the transition to heart failure, suggesting that it is a promising agent in the treatment of cardiac diseases."
3.	Heart Diseases (Heart Disease) 09/01/2017 - "Our results demonstrate that C33(S) effectively protects against cardiac hypertrophy and postpones the transition to heart failure, suggesting that it is a promising agent in the treatment of cardiac diseases."

Related Drugs and Biologics

1.	phospholamban

Related Therapies and Procedures

1.	Oral Administration